Our study also revealed that GLP-1 RA use was associated with a significantly lower risk of cardiovascular diseases and cardiovascular mortality than GLP-1 RA no-use in patients with T2D and without viral hepatitis. The gene discussed is GCG; the disease is viral hepatitis.